Benefits of Hot Melt Extrusion Presented at Drug Development Networking Summit
SOMERSET, N.J. – April 9, 2019 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Ms. Marlene Leuenberger, General Manager of the company’s Somerset, New Jersey drug development center of excellence, will present at the upcoming 4th Annual Drug Development Networking Summit at the Bridgewater Marriott Hotel, Bridgewater, New Jersey, on April 11, 2019.
At 8:45 a.m., Ms. Leuenberger will discuss hot melt extrusion (HME), a novel technique that offers several advantages, including the development of physically stable and processable amorphous forms of active pharmaceutical ingredients (APIs), controlled and modified drug delivery to improve bioavailability, as well as taste masking. The presentation, titled, “Hot Melt Extrusion for Improved Drug Delivery,” will discuss the most common uses of HME, and will explain how an integrated end-to-end HME process provides the capability to formulate, develop, and commercialize differentiated dosage forms.
Catalent recently announced it has invested a further $5 million at the company’s Somerset drug development center of excellence to expand its OptiMelt® HME capabilities.
Ms. Leuenberger has over 25 years’ management experience in engineering, quality operations and plant management within the biotech and pharmaceutical industries, and previously held senior positions in operations at Impax Laboratories, LTS Lohmann Therapy Systems Corp., Novartis Consumer Health, Wyeth (now Pfizer), and Procter and Gamble. Ms. Leuenberger has a bachelor’s degree in chemical engineering from Clarkson University, New York.
On Friday, April 12, Catalent will host a breakfast and site tour event at its Somerset facility. For more information, please visit this page.
To arrange a meeting with any of the attending Catalent executives at the event, contact Richard Kerns at NEPR – richard@nepr.agency
Media Contacts:
Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com
Richard Kerns
+44 (0)161 728 5880
richard@nepr.agency
About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.